- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
GNI Group Ltd (2160)
The GNI share price today is 2,984.0, view TYO 2160 stock exchange data. Track the latest GNI share price with real-time updates on 2160 stock performance including market cap, day range, 52-week range and dividend yield. Access 2160 charts, earnings dates and analyst estimates to support your investment decisions.
2,984.0
-16.0(-0.53%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2,953.0
3,050.0
52 wk Range
2,112.0
4,410.0
Earnings results expected in 3 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2,953.03,050.0
52 wk Range
2,112.04,410.0
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
2160 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
4,400.0
Upside
+47.45%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Prominent player in the Biotechnology industry
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 4,400.0
(+47.45% Upside)
Earnings
Latest Release
13-02-2026
EPS / Forecast
-74.44 / 224.64
Revenue / Forecast
7.48B / 11.41B
Compare 2160 to Peers and Sector
Metrics to compare | 2160 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2160PeersSector | |
|---|---|---|---|---|
P/E Ratio | −39.7x | −6.2x | −0.6x | |
PEG Ratio | 0.08 | −0.10 | 0.00 | |
Price/Book | 3.3x | 4.1x | 2.6x | |
Price / LTM Sales | 6.3x | 35.8x | 3.2x | |
Upside (Analyst Target) | 41.7% | 140.9% | 49.4% | |
Fair Value Upside | Unlock | 10.6% | 6.0% | Unlock |
GNI Group Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of pharmaceuticals and biomaterials in Japan, China, and the United States. It operates in two segments, Pharmaceutical Business and Medical Equipment Business. The company offers ETUARY for the treatment of idiopathic pulmonary fibrosis; H-GENIN Crush-Mix for the treatment of bone defects; AltiPly for the treatment of acute and chronic wounds; and orthobiologics products. It also develops ETUARY which is in Phase III clinical trial for the treatment of pneumoconiosis, dermatomyositis interstitial lung disease, and systemic sclerosis-associated interstitial lung disease; and F351 which is in Phase III clinical trial for the treatment of chronic hepatitis B liver fibrosis. In addition, the company is involved in the development of ETUARY which is in Phase II clinical trial for the treatment of radiation-induced lung injury with or without immune-related pneumonitis; F573 which is in Phase II clinical trial for the treatment of acute liver failure and acute-on-chronic liver failure; F351 which is in Phase I clinical trial for the treatment of MASH-advanced liver fibrosis; and F230 which is in Phase I clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops CG001419 which is in Phase Ia clinical trial for the treatment of acute and chronic pain; CG001419 which is in Phase Ia clinical trial for the treatment of solid tumors; and CG009301 which is in Phase Ia clinical trial for the treatment of leukemia and MYC+ cancers. The company was incorporated in 2001 and is headquartered in Chuo, Japan.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the GNI (2160) Share Price Today?
The GNI share price today is 2,984.0.
What is the current GNI (2160) share price and day range?
As of 12-05-2026, the GNI share price is 2,984.0, with a previous close of 3,000.0. The share price has ranged from 2,953.0 to 3,050.0 today, while the 52-week range spans from 2,112.0 to 4,410.0.
What Is the GNI Market Cap?
As of today, GNI market cap is 167.54B.
What Is the GNI (2160) Share Price Target?
The average 12-month share price target for GNI is 4,400.0, with a high estimate of 5000 and a low estimate of 3800. 3 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +47.45% Upside potential.
What Is GNI's Earnings Per Share (TTM)?
The GNI EPS (TTM) is -80.9.
When Is the Next GNI Earnings Date?
GNI will release its next earnings report on 15-05-2026.
From a Technical Analysis Perspective, Is 2160 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does GNI Trade On?
GNI is listed and trades on the Tokyo Stock Exchange.
What Is the Stock Symbol for GNI?
The stock symbol for GNI is "2160."
How Many Times Has GNI Stock Split?
GNI has split 2 times.
How Many Employees Does GNI Have?
GNI has 990 employees.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.